Veru posts Q3 loss, reports full enrollment in obesity drug trial

August 10, 2026 6:30 AM

Veru Inc. (NASDAQ: VERU) reported a net loss of $7.0 million, or $0.30 per share, for its fiscal third quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found